We’re Making History!
Anika History

2024
Commenced full market release of the Integrity™ Implant System, a regenerative hyaluronic acid-based scaffold for tendon repair, along with its complete arthroscopic instrumentation platform for rotator cuff repair.
Completed the divestiture of its Arthrosurface business to Phoenix Brio, Incorporated.
2023
Received 510(k) clearance then commenced limited market release after performing first surgeries using the Integrity Implant System.
Completed enrollment in Hyalofast® pivotal Phase III clinical study, a key milestone in its path to achieving US FDA approval.
Tactoset® received additional FDA 510(k) clearance to be combined with autogenous bone marrow aspirate (BMA).
2021
FDA 510(k) clearance received for Tactoset Injectable Bone Substitute to include a new indication for augmentation of hardware, including suture anchors.
Competed enrollment for US pilot clinical study of Cingal, a combination hyaluronic acid (HA) and fast-acting steroid injection for osteoarthritis knee pain.
2020
Anika acquired Arthrosurface, a leading, privately-held provider of joint preservation solutions, and Parcus Medical, a leading, privately-held sports medicine company.
Cheryl R. Blanchard, Ph.D., appointed as President and Chief Executive Officer.
2016
International launch of Cingal, the first HA-based viscosupplement plus steroid combination product for the treatment of osteoarthritis pain.
CE Mark approval received for Orthovisc®-T, a treatment designed to relieve pain and restore function for patients with chronic tennis elbow.
2009
Acquired technology used in Hyalofast, a one-step cartilage regeneration product, through the strategic acquisition of Fidia Advanced Biopolymers, a leading innovator in hyaluronic acid-based tissue engineered products, based in Abano Terme, Italy.
Hyalofast received CE mark approval and launched internationally.
1992
Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc.
Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc® and Amvisc® Plus.